New Modalities

CPSA is an ingenious extension of the target engagement toolbox. It is easier to upscale and control in high throughput screening applications than currently available methods. With exemplary support from MDC we have smoothly incorporated it into our Drug Discovery pipeline.

MDC’s R&D consulting has been transformative, refining our HT8457S strategy with scientific rigour, identifying and mitigating risks, and strengthening our business model, significantly enhancing Haiku’s credibility.

The partnership with MDC has allowed us to secure multiple Innovate UK grants and utilise capabilities such as state-of-the-art PET, which aren’t available elsewhere.

For the first time, we have been able to generate a map of lung fibrosis in 3D at the tissue scale. Collaborating with MDC has been key to its success. Their expertise has supported the successful integration of state-of-the-art technologies, establishing a valuable new resource for the lung fibrosis community.

Working with MDC allowed us to visualise drug distribution in the brain with a level of clarity we hadn’t achieved before. Their expertise in DESI-MS and willingness to design a project that met our demands provided powerful insights into diffusion patterns, giving us confidence in our compound’s delivery.

We worked with the Mass Spectrometry team at MDC to help set up and run a complex biochemical assay. The project was technically demanding, but the deep expertise, knowledge and collaborative approach allowed the team to troubleshoot the many challenges and successfully deliver a viable approach.

The team at MDC shares our passion for bringing forward innovative medicines, pioneering new technologies, and operating with data-driven flexibility. They have been integral to our project success and possess unique capabilities to support later-stage candidate selection. A truly valued collaborator and dependable partner.

Elasmogen was impressed by the quality and rapid delivery timelines for our radiopharmaceutical dosimetry data. There was good interactivity in this project, and we are happy to recommend this service.

Our collaboration with Medicines Discovery Catapult will not only enable us to engage with the wider scientific community but will also allow us to unlock the potential of Acoustic Mass Spectrometry within drug discovery.

It’s been absolutely amazing working with MDC and the team.

MDC supported us in developing a therapeutic for Huntington’s Disease through antibody characterisation, iPSC model development, biodistribution studies, imaging and neurodegenerative expertise.

We worked together with MDC on a very challenging and demanding project. The MDC team’s expertise in MSI, commitment and flexibility were key to a successful collaboration and reaching our objectives.

MDC are as involved in our project as the founding team, going above and beyond what I expected. I recommend them to new ventures starting out; even if you don’t know exactly what you need, the team can work with you to achieve some phenomenal results.

Working with MDC has provided expertise and intellectual input. It has also enabled access to a wider network of companies providing specialist services.

By tapping into MDC’s unique drug development expertise and facilities, we are confident we will accelerate the preclinical development of our drug delivery system and its commercialisation.

It has been a pleasure working with MDC as their scientists are pleasant and have a broad range of talents.
Importantly for projects like ours, they openly and professionally exchange ideas with SMi’s scientific team and keep us abreast of their research developments.

It has been great to access the Artificial Intelligence expertise at Medicines Discovery Catapult.
The team has taken an innovative approach that adds value to our product and will benefit our customers.

As an SME, working with MDC allows us access to scientific know-how and in vivo imaging techniques that would be impossible through any other route. The closeness, timeliness and flexibility of the collaboration significantly accelerated our ability to develop the product.

We have collaborated with MDC for three years, and it continues to provide valuable and high-quality data on our molecules. MDC’s input has directly impacted operational and strategic decisions for our projects and allowed us to move forward with our clinical studies.

For early-stage SMEs in this space, I thoroughly recommend engaging with MDC, who have the end-to-end knowledge in complex medicines, can support your in-house team and provide access to key equipment that start-ups may not have.